Advancing science, creating impact
Skygene is a venture capital firm focused on supporting the next generation of bioprocessing and biotech companies. We partner with visionary founders in the seed, Series A, and Series B stages, enabling breakthrough technologies to reach their full potential.
​
Founded by biotech entrepreneurs with deep industry knowledge, we invest in companies with an advanced technological edge and strong leadership.As founders and entrepreneurs ourselves, we know the journey of building a biotech company and understand the unique challenges that scientific founders face. We believe in nurturing their growth, helping them scale their organizations, and guiding them through the critical stages of early revenue generation.
Join us as we advance science and create lasting impact through transformative innovation in life sciences.
Meet the Skygene Team
Our team is composed of seasoned biotech entrepreneurs and venture capitalists who bring decades of industry experience, success in scaling businesses, and a track record of impactful investments.
Partner
Martin Wodak
Martin brings over twenty years of venture capital experience in the bioprocessing sector. As the former CFO of BIA Separations, he played a crucial role in the sale to Sartorius in 2020. Martin’s deep expertise in guiding companies through high-stakes growth and strategic exits is a pillar of Skygene’s success.
Partner
Ingo Nagler
Ingo’s extensive experience in business development within the bioprocessing and life sciences fields makes him a key asset. A co-founder of BIA-Separation, now part of Sartorius, Ingo understands the pathways to growth and impact in the bioprocessing industry.
Partner
Harry Boeltz
With over twenty years in leadership roles within life sciences, Harry is a full-cycle entrepreneur. He founded Dispendix, which later became part of Cellink. Harry’s hands-on experience in founding and scaling companies brings valuable perspective to the Skygeneportfolio.
Partner
Bertrand Coissac
Bertrand founded Geneye, now part of Tracamyl, and Biowire, now integrated into Polyplus. As VP of Corporate Development at Polyplus, he led acquisitions of eZyvec, Xpress Biologics, and Bioelpida before supporting Polyplus’ exit to Sartorius in 2023. Bertrand’s expertise in strategic development and acquisitions strengthens Skygene’s ability to drive portfolio growth.
Our Portfolio
Skygene partners with early-stage companies that are setting new benchmarks in biotechnology and life sciences. Below are some of our pioneering portfolio companies.
Ribbon Bio is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies. With their automated, enzyme-based platform, Ribbon Biolabs can provide synthetic DNA molecules without size or sequence limitations at a high level of accuracy and at unprecedented speed.
Valanx has developed a novel site-specific protein conjugation platform leveraging synthetic biology and genetic code expansion. It allows precise control over conjugation site and number of conjugations on the protein of interest. Based on this platform Valanx is developing a number of cutting-edge biologics towards potential treatments for various indications.
Skygene’s portfolio is carefully curated to include innovative companies that align with our mission of advancing science and creating tangible impact. We are committed to empowering visionary founders and enabling their cutting-edge solutions to thrive in the marketplace.